A phase II, multicenter, open-label, dose-finding study evaluating THIO sequenced with cemiplimab in patients with advanced NSCLC

被引：0
|
作者：
Ciuleanu, T-E. [1 ]
Joshi, R. [2 ]
Gryaznov, S. [3 ]
Vitoc, V. [3 ]
Obrocea, M. [3 ]
机构：
[1] IOCN Oncol Inst Prof Dr Ion Chiricuta, Med Oncol, Cluj Napoca, Romania
[2] Canc Res SA, Med Oncol, Adelaide, SA, Australia
[3] MAIA Biotechnol Inc, Clin Dev, Chicago, IL USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
10.1016/j.annonc.2022.07.1316
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1193TiP
引用
收藏
页码：S1094 / S1094
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study
    Enya, Kazuaki
    Saji, Ben T.
    Kato, Takuya
    Okamoto, Hiroyuki
    Koumura, Emiko
    ADVANCES IN THERAPY, 2018, 35 (08) : 1181 - 1190
  • [32] Pharmacokinetics of a Single Dose of Azilsartan in Pediatric Patients: A Phase 3, Open-Label, Multicenter Study
    Kazuaki Enya
    Ben T. Saji
    Takuya Kato
    Hiroyuki Okamoto
    Emiko Koumura
    Advances in Therapy, 2018, 35 : 1181 - 1190
  • [33] Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma
    Duvic, Madeleine
    Kim, Youn H.
    Zinzani, Pier Luigi
    Horwitz, Steven M.
    CLINICAL CANCER RESEARCH, 2017, 23 (14) : 3552 - 3556
  • [34] Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: an open-label, multicenter Phase I study
    Saunders, M.
    Van Cutsem, E.
    Wilson, R.
    Peeters, M.
    Smith, R.
    Godwood, A.
    Oliver, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
  • [36] Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE) :an open-label, phase 2a dose-finding study
    Salamero, Olga
    Molero, Antonieta
    Perez-Simon, Jose Antonio
    Arnan, Montserrat
    Coll, Rosa
    Garcia-Avila, Sara
    Acuna-Cruz, Evelyn
    Cano, Isabel
    Somervaille, Tim C. P.
    Gutierrez, Sonia
    Arevalo, Maria Isabel
    Xaus, Jordi
    Buesa, Carlos
    Limon, Ana
    Faller, Douglas, V
    Bosch, Francesc
    Montesinos, Pau
    LANCET HAEMATOLOGY, 2024, 11 (07): : e487 - e498
  • [37] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Shuntaro Obi
    Shigetoshi Fujiyama
    Shuichiro Shiina
    Hideyuki Tamai
    Hitoshi Mochizuki
    Yukihiro Koike
    Jun Imamura
    Takayoshi Yamaguchi
    Isamu Saida
    Osamu Yokosuka
    Masao Omata
    Hepatology International, 2014, 8 : 94 - 103
  • [38] A multicenter, phase Ib/II, open-label study of tivozanib with durvalumab in advanced hepatocellular carcinoma (DEDUCTIVE)
    Mahmood, Sharmeen
    Li, Daneng
    Lee, Arielle
    Rowe, Julie
    Beg, Muhammed
    Kasturi, Vijay
    Iyer, Renuka
    Abrams, Thomas
    Dayyani, Farshid
    FUTURE ONCOLOGY, 2022, 18 (40) : 4465 - 4471
  • [39] AN OPEN-LABEL PHASE 2, DOSE-FINDING STUDY OF THE SAFETY AND EFFICACY OF RUSFERTIDE (PTG-300), A HEPCIDIN MIMETIC, IN PATIENTS WITH HEREDITARY HEMOCHROMATOSIS
    Kowdley, Kris V.
    Modi, Nishit
    Valone, Frank
    Priego, Victor
    Cole, Frank
    Pouzar, Joe
    Gupta, Suneel
    HEPATOLOGY, 2021, 74 : 24A - 25A
  • [40] A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer
    Anthony W. Tolcher
    Leonard J. Appleman
    Geoffrey I. Shapiro
    Alain C. Mita
    Frank Cihon
    Arthur Mazzu
    Pavur R. Sundaresan
    Cancer Chemotherapy and Pharmacology, 2011, 67 : 751 - 764
12345